CA3142226A1 - Method of providing safe administration of an anti-cd40 antibody - Google Patents

Method of providing safe administration of an anti-cd40 antibody Download PDF

Info

Publication number
CA3142226A1
CA3142226A1 CA3142226A CA3142226A CA3142226A1 CA 3142226 A1 CA3142226 A1 CA 3142226A1 CA 3142226 A CA3142226 A CA 3142226A CA 3142226 A CA3142226 A CA 3142226A CA 3142226 A1 CA3142226 A1 CA 3142226A1
Authority
CA
Canada
Prior art keywords
antibody
variable region
chain variable
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142226A
Other languages
English (en)
French (fr)
Inventor
Michael Streit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CA3142226A1 publication Critical patent/CA3142226A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3142226A 2019-05-28 2020-05-27 Method of providing safe administration of an anti-cd40 antibody Pending CA3142226A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853488P 2019-05-28 2019-05-28
US62/853,488 2019-05-28
PCT/IB2020/055023 WO2020240434A1 (en) 2019-05-28 2020-05-27 Method of providing safe administration of an anti-cd40 antibody

Publications (1)

Publication Number Publication Date
CA3142226A1 true CA3142226A1 (en) 2020-12-03

Family

ID=70918772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142226A Pending CA3142226A1 (en) 2019-05-28 2020-05-27 Method of providing safe administration of an anti-cd40 antibody

Country Status (13)

Country Link
US (1) US20230174658A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976651A1 (cg-RX-API-DMAC7.html)
JP (2) JP7755999B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220012918A (cg-RX-API-DMAC7.html)
CN (1) CN113939535A (cg-RX-API-DMAC7.html)
AU (1) AU2020284706A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023906A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142226A1 (cg-RX-API-DMAC7.html)
IL (1) IL288288A (cg-RX-API-DMAC7.html)
MA (1) MA56027A (cg-RX-API-DMAC7.html)
MX (1) MX2021014572A (cg-RX-API-DMAC7.html)
SG (1) SG11202112909SA (cg-RX-API-DMAC7.html)
WO (1) WO2020240434A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122355A2 (en) * 2021-12-24 2023-06-29 Sapience Therapeutics, Inc. Methods of treating or preventing infusion-related reactions
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003557A1 (en) * 2005-04-21 2007-01-04 Andres Forero Method for treating cancer using premedication
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
EP3180087B1 (en) * 2014-08-12 2019-03-13 Alligator Bioscience AB Combination therapies with anti cd40 antibodies
WO2018160917A1 (en) * 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer

Also Published As

Publication number Publication date
SG11202112909SA (en) 2021-12-30
BR112021023906A2 (pt) 2022-01-25
JP2026004525A (ja) 2026-01-14
JP2022534494A (ja) 2022-08-01
CN113939535A (zh) 2022-01-14
IL288288A (en) 2022-01-01
MA56027A (fr) 2022-04-06
KR20220012918A (ko) 2022-02-04
US20230174658A1 (en) 2023-06-08
JP7755999B2 (ja) 2025-10-17
WO2020240434A1 (en) 2020-12-03
MX2021014572A (es) 2022-03-17
AU2020284706A1 (en) 2021-12-16
EP3976651A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
US20250163155A1 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
KR100847944B1 (ko) Cd40 항체 제제 및 방법
JP2026004525A (ja) 抗cd40抗体の安全な投与を提供する方法
CN118453840A (zh) 用于调节免疫应答的方法
JP2016534090A (ja) Cd38アゴニストの医学的使用
US20230340122A1 (en) Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
EP3039039B1 (en) Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
JP2021518854A (ja) T1dm及び膵島炎の治療に使用するための抗cd40抗体
TWI728400B (zh) Cd226促效劑抗體
CA3082117A1 (en) Methods and compositions for treating cancer by modifying multiple arms of the immune system
CN119173276A (zh) 用于治疗表达Trop-2的癌症的组合疗法
KR20240038008A (ko) 암 치료 방법 및 조성물
EP4329808A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
EP4516314A1 (en) Combination of anti-pd-1 antibody and anti-egfr antibody, and use thereof in treatment of head and neck squamous cell carcinoma
US20030096317A1 (en) Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
HK40067213A (en) Method of providing safe administration of an anti-cd40 antibody
US20210317220A1 (en) Method of providing safe administration of an anti-cd154 antibody
US20250177520A1 (en) Methods for the treatment of multiple myeloma
US20250269019A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20220062390A1 (en) Methods of treating cancer
JP2020526568A (ja) 抗cd20抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗cd19抗体を用いるb細胞悪性の治療
HK40109234A (en) Methods and compositions for treating cancer
HK40011069A (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
HK40011069B (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240502

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250515

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250515

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250919